


IN THE CLAIMS

Claims 1-41 (canceled)

42. (New) A compound of Formula I



wherein:

R¹, R² and R³ are independently in each occurrence hydrogen, halogen, (C₁₋₆) - alkyl, -OR', -SR', -NR'R'', -SOR', -SO₂R', -COOR', -OCOR', -OCONR'R'', -OSO₂R', -OSO₂NR'R'', -NR'SO₂R'', -NR'COR'', -SO₂NR'R'', -SO₂(CH₂)₁₋₃CONR'R'', -CONR'R'', cyano, haloalkyl, or nitro; or R¹ and R² if adjacent, taken together with the carbons to which they are attached may also form a 5- to 7- membered aromatic, saturated or unsaturated ring, optionally incorporating one or two ring heteroatoms chosen from N, S (O)₀₋₂, or O, and optionally substituted with (C₁₋₆)-alkyl, halo, cyano or lower alkoxy;

R' and R'' are independently in each occurrence hydrogen, (C₁₋₆)-alkyl, substituted lower alkyl, (C₀₋₃)alkylalkoxy, aryl, heterocyclyl, heteroaryl, aryl-(C₁₋₃)-alkyl, heteroaryl-(C₁₋₃)-alkyl, heterocyclyl-(C₁₋₃)-alkyl, cycloalkylalkyl, cycloalkyl, or R' and R'' together with the nitrogen they are attached may also form a 5- to 7- membered ring, optionally incorporating one additional ring heteroatom chosen from N, O or S(O)₀₋₂;

R⁴ is independently in each occurrence (C₁₋₆) alkyl;

R⁵ is independently in each occurrence (C₁₋₆) alkyl, (C₁₋₆) alkenyl, (C₁₋₆) alkynyl, or cycloalkyl;

one of X, Y or Z is independently S, O, or N-R⁶, the others are CH₂;

R⁶ is hydrogen, (C₁₋₆)-alkyl, haloalkyl, aryl(C₁₋₆)alkyl, heteroaryl(C₁₋₆)alkyl, -(C₁₋₆)-CR'R'R', -COOR', -SO₂R', -C(O)R', -SO₂(CH₂)₀₋₃NR'R'', -CONR'R'', -C(O)OCH₂OC(O)R', -C(O)OCH₂SC(O)R', or -PO(OR')₂, where R' and R'' are as defined above;

m is 1;

n is an integer from 1 to 6 inclusive;
or pharmaceutically acceptable salts or solvates thereof.

43. (New) The compound of Claim 42, wherein n is 3.
44. (New) The compound of Claim 42, wherein R⁴ is methyl.
45. (New) The compound of Claim 42, wherein n is 3 and R⁴ is methyl.
46. (New) The compound of Claim 42, wherein X is S or O.
47. (New) The compound of Claim 42, wherein Y is S or O.
48. (New) The compound of Claim 42, wherein Z is S or O.
49. (New) The compound of Claim 42, wherein one of X, Y or Z is NR⁶, and the others are CH₂.
50. (New) The compound of Claim 49, wherein X is NH.
51. (New) The compound of Claim 49, wherein Y is NH.
52. (New) The compound of Claim 49, wherein Z is NH.
53. (New) The compound of claim 42, wherein X is S, O, or N-R⁶, and Y and Z are CH₂.
54. (New) The compound of claim 43, wherein X is S or O, and Y and Z are CH₂.

55. (New) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 42 in admixture with a pharmaceutically acceptable carrier.
56. (New) The pharmaceutical composition of Claim 55 wherein the compound is suitable for administration to a subject having a disease state which is alleviated by treatment with a M2/M3 muscarinic receptor antagonist.
57. (New) A method for treating a subject suffering from a smooth muscle function disease mediated by an M2/M3 muscarinic receptor antagonist, said method comprising administering to said subject an effective amount of at least one compound of claim 42.
58. (New) The method of claim 57, wherein said smooth muscle function disease comprises detrusor hyperactivity.
59. (New) The method of claim 57, wherein said smooth muscle function disease comprises unstable bladder contractions.